eCORE
- Brain & Mind and Behaviour
- Chronic, Prevalent Diseases & Aging
- Woman & Child Health & Rare Diseases
Team
Group Leader
Patricia Pozo Rosich
Principal Investigator (PI)
Marta Torres-Ferrus, Marta Vila-Pueyo
Researchers
Edoardo Caronna, Victor J Gallardo, Alicia Alpuente, Nara Ikumi
PhD Students
Joana Rosell Miami, Otilia Gliga, Rut Mas de les Valls
Lab Technicians
Laila Asskour
Nursing and Technical Staff
Eulalia Giné Ciprés, Raquel Lastra, Estefania Muñoz
Selected Publications
Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P (CA); EUREkA study group
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
J Neurol Neurosurg Psychiatry 2024;95:927-937
DOI: 10.1136/jnnp-2023-333295
IF: 8.800
Pozo-Rosich P (CA), Dolezil D, Paemelaire K, Stephen A, Stude P, Snellman J, Arkuszewski M, Stites T, Ritter S, Lopez Lopez C, Maca J, Ferraris M, Gil-Gouveia R.
Early use of erenumab vs nonspecific oral migraine preventives. The APPRAISE randomized clinical trial
JAMA Neurology 2024:81(5):461-470
DOI: 10.1001/jamaneurol.2024.0368
IF: 20.900
Pozo-Rosich P (CA), Alpuente A, Silberstein SD, Burstein R
Insights from 25 years of onabotulinumtoxinA in migraine – mechanisms and management
Nat Rev Neurol 2024;20:555-568
DOI: 10.1038/s41582-024-01002-5
IF: 28.2
Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (CA
Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population
Journal Headache Pain 2024;25:21
DOI: 10.1186/s10194-024-01727-0
IF: 7.300
Torres- Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (CA)
Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies
Cephalalgia 2024;44:3331024231222923
DOI: 10.1177/03331024231222923
IF: 5.000
Selected Projects
PREDIMIGRAINE: Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti- CGRP utilizando estrategias multi-ómicas
Principal Investigator: Patricia Pozo-Rosich
Agency: Instituto Salud Carlos III – PMP22/00189
Funding: 377,633.30€
Period: 2022-2025
FAST: Fenotipado molecular de pacientes con migraña según edad y sexo a través de la cuantificación de CGRP en saliva para realizar medicinad de precisión
Principal Investigator: Patricia Pozo-Rosich
Agency: Instituto Salud Carlos III – ISCIII (AES) – PI22/01501
Funding: 81,070€
Period: 2022-2025
BIOMIGA: A multidisciplinary approach to the identification of BIOmarkers of MIGraine: a proof of concept study based on the stratification of responders to CGRP monoclonal Antibodies
Principal Investigator: Patricia Pozo-Rosich
Agency: Instituto de Salud Carlos III/ERANet Neuron – AC19/00124
Funding: 175,000€
Period: 2020-2024
MAMBO:BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña
Principal Investigator: Marta Torres-Ferrus
Agency: Instituto Salud Carlos III
Funding: 78,000€
Period: 2022-2025
Study of the glia in an animal model of migraine
Principal Investigator: Marta Vila-Pueyo
Agency: la Caixa Junior Leader
Funding: 305,000€
Period: 2024-2026
Selected Dissemination Activities
Awareness Webinars
Place: Online
Date: 26/07/2025
Brief: Our research group organizes webinars to inform society and people with headache and migraine about the disease, research and therapeutic options
